DE602005027226D1 - Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon - Google Patents

Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon

Info

Publication number
DE602005027226D1
DE602005027226D1 DE602005027226T DE602005027226T DE602005027226D1 DE 602005027226 D1 DE602005027226 D1 DE 602005027226D1 DE 602005027226 T DE602005027226 T DE 602005027226T DE 602005027226 T DE602005027226 T DE 602005027226T DE 602005027226 D1 DE602005027226 D1 DE 602005027226D1
Authority
DE
Germany
Prior art keywords
variants
viral
present
virus
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005027226T
Other languages
English (en)
Inventor
Julie Sheldon
Berta Rodes
Vincent Soriano
Angeline Ingrid Bartholomeusz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melbourne Health
Fundacion Investigacion y Educacion En Sida
Original Assignee
Melbourne Health
Fundacion Investigacion y Educacion En Sida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905615A external-priority patent/AU2004905615A0/en
Application filed by Melbourne Health, Fundacion Investigacion y Educacion En Sida filed Critical Melbourne Health
Publication of DE602005027226D1 publication Critical patent/DE602005027226D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005027226T 2004-09-28 2005-09-28 Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon Active DE602005027226D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004905615A AU2004905615A0 (en) 2004-09-28 Viral variants and applications thereof
PCT/AU2005/001489 WO2006034545A1 (en) 2004-09-28 2005-09-28 Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof

Publications (1)

Publication Number Publication Date
DE602005027226D1 true DE602005027226D1 (de) 2011-05-12

Family

ID=36118509

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005027226T Active DE602005027226D1 (de) 2004-09-28 2005-09-28 Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon

Country Status (6)

Country Link
US (1) US7927601B2 (de)
EP (1) EP1799814B1 (de)
AT (1) ATE503830T1 (de)
DE (1) DE602005027226D1 (de)
WO (1) WO2006034545A1 (de)
ZA (1) ZA200702632B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP2033967A1 (de) 2002-04-12 2009-03-11 Melbourne Health Hepatitis-B-Virusvarianten mit reduzierter Suszeptibilität für Nukleosidanaloga und Verwendungen dafür
EP1874923A4 (de) 2005-04-08 2010-08-04 Melbourne Health Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon
AU2006230802A1 (en) 2005-04-08 2006-10-12 Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
EP1948800B1 (de) * 2005-10-21 2015-12-23 Melbourne Health Antivirale resistenzmutanten und deren anwendungen
US8859198B2 (en) 2006-06-06 2014-10-14 Abl Sa Detection and use of antiviral resistance mutations
WO2011039612A1 (en) * 2009-10-01 2011-04-07 Ranjit Chauhan Detection and use of antiviral resistance mutations
CR20190207A (es) 2011-04-21 2019-06-26 Ionis Pharmaceuticals Inc MODULACIÓN DE LA EXPRESIÓN DEL VIRUS DE LA HEPATITIS B (VHB) (Divisional 2013-0551)
CN102807971B (zh) * 2011-06-09 2014-02-12 复旦大学附属华山医院 高表达耐拉米夫定hbv病毒肝癌细胞株
EP3148566B1 (de) 2014-06-02 2024-04-03 ISA Pharmaceuticals B.V. Synthetische, lange peptide (slp) zur therapeutischen impfung gegen hepatitis-b-virusinfektion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309379A1 (en) * 2000-06-09 2001-12-09 Thomas Bock Viral variants and uses therefor
CA2475446C (en) 2002-02-07 2014-05-06 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP2033967A1 (de) * 2002-04-12 2009-03-11 Melbourne Health Hepatitis-B-Virusvarianten mit reduzierter Suszeptibilität für Nukleosidanaloga und Verwendungen dafür
AU2003279103A1 (en) * 2002-10-01 2004-04-23 Gilead Sciences, Inc. Hbv mutations associated with reduced susceptibility to adefovir
AU2004285983B2 (en) 2003-10-21 2012-06-28 Alfred Health HBV variants detection and application

Also Published As

Publication number Publication date
ZA200702632B (en) 2008-08-27
US20100047281A1 (en) 2010-02-25
EP1799814A1 (de) 2007-06-27
ATE503830T1 (de) 2011-04-15
US7927601B2 (en) 2011-04-19
WO2006034545A1 (en) 2006-04-06
EP1799814A4 (de) 2008-02-20
EP1799814B1 (de) 2011-03-30

Similar Documents

Publication Publication Date Title
DE602005027226D1 (de) Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon
SG161255A1 (en) Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof
Hatzakis et al. HBV virological assessment
Ning et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)
EP1476543A4 (de) Virusvarianten mit veränderter empfindlichkeit gegenüber nukleosidanalogen und verwendungen davon
Xu et al. Acute hepatitis B infection associated with drug-resistant hepatitis B virus
Feng et al. A novel genotype of GB virus C: its identification and predominance among injecting drug users in Yunnan, China
Brichler et al. Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia
Cubero et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient
Attar et al. A new twist to a chronic HCV infection: occult hepatitis C
Mixson-Hayden et al. Performance of ARCHITECT HCV core antigen test with specimens from US plasma donors and injecting drug users
Tillmann et al. GB virus-C infection in patients infected with the human immunodeficiency virus
Tsuge et al. G to A hypermutation of TT virus
EP2404933A3 (de) HBV-Variantenerkennung und Anwendung
Saito et al. Transmission of hepatitis C virus: self-limiting hepatitis or chronic hepatitis?
ATE534729T1 (de) Hepatitis-b-virus-dna-polymerase und oberflächenantigen-varianten und methoden iher verwendung
Gerken et al. Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA
Twagirumugabe et al. Low prevalence of hepatitis C virus RNA in blood donors with anti‐hepatitis C virus reactivity in Rwanda
Pan et al. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine‐resistant hepatitis B genotypes B and C
Ursu et al. Laboratory diagnosis for optimize therapy of B hepatitis virus infection by using biochemical and molecular biology methods
Hong et al. Role of HBsAg testing in the management of patients with chronic HBV
Gupta et al. Analysis of mutations within the 5′ untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in hepatitis C virus-infected patients in India
Berzsenyi et al. GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease
Krekulova et al. Genotypic distribution of hepatitis B virus in the Czech Republic: a possible association with modes of transmission and clinical outcome
Santer et al. A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression